Visão geral da empresa
A biopharmaceutical entity, MediciNova, Inc. dedicates its operational resources to the research and development of novel small molecule therapeutics aimed at addressing serious diseases with unmet medical needs within the United States market. The company operates specifically within the healthcare sector, functioning as a biotechnology firm that targets conditions lacking effective current treatment options. Its current operational scale is defined by a market capitalization of $69.89M, an annual revenue generation of $409,657 over the trailing twelve months, and a workforce comprised of 6 employees. These financial figures indicate that the company operates with a relatively small market presence and limited revenue base relative to its valuation metrics, suggesting a position typical for early-stage biotechnology entities where significant capital is allocated toward clinical trials rather than broad commercialization.
Saúde financeira
Over the trailing twelve months, the company reported a revenue of $409,657, a net income loss of $-11,997,957, and an EBITDA of $-13,262,903, revealing a substantial disparity between top-line revenue generation and bottom-line profitability. The significant gap between the minimal revenue and the massive net income loss highlights an aggressive cost structure driven primarily by the high expenditures associated with developing MN-166 (ibudilast) during Phase 2 clinical trials. Free cash flow stands at $-6,088,045, indicating that the company is burning cash rapidly to fund its R&D pipeline, which necessitates access to external capital markets or existing cash reserves to maintain operations. The gross margin is recorded at 7.6%, while the operating margin reaches -2038.0% and the profit margin sits at 0.0%, collectively illustrating that current business activities are heavily loss-making at both the operational and net income levels. On the balance sheet, the company holds $30.81M in cash against a total debt obligation of $211,460, resulting in a debt-to-equity ratio of 0.51, which suggests a conservative leverage profile despite the operational losses. The current ratio of 8.16 indicates a very strong short-term liquidity position, providing ample coverage for current liabilities with available cash resources. Return on Equity is -25.5% and Return on Assets is -16.4%, metrics that reveal that management is currently generating negative returns on shareholder equity and total assets due to the capital-intensive nature of the clinical development phase.
Avaliação de valorização
The valuation metrics present a trailing P/E ratio of N/A and a forward P/E of -3.42, implying that the market is pricing in a path toward future profitability that has not yet been realized in historical earnings data. A price-to-book ratio of 1.68 indicates that the market values the company at a 68% premium over its net asset value, reflecting investor confidence in the potential value of its intellectual property and clinical pipeline despite current losses. Alternative valuation measures such as the price-to-sales ratio of 170.62 and an EV/EBITDA of -2.96 further suggest that the stock is priced based on future growth expectations rather than current cash flow generation or earnings power. Regarding trading range, the 52-week high is $1.96 and the 52-week low is $1.17, meaning the current price sits below the 52-week high and above the 52-week low within this historical band. The beta value of 0.61 indicates that the stock price exhibits lower volatility relative to the broader market, moving with less intensity than the overall market index during periods of price fluctuation.
Growth & Income
Revenue growth year-over-year is listed as N/A and earnings growth year-over-year is also N/A, preventing a direct comparison of earnings expansion versus revenue expansion at this specific data point. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, meaning the entity reinvests all available financial resources, including the $30.81M cash reserve, into research, development, and clinical trial expenses rather than returning capital to shareholders. The overall growth and income profile is characterized by a lack of current income distribution and undefined historical growth rates, focusing entirely on capital allocation toward the advancement of its therapeutic candidates.